nach oben

Sleep and Breathing

Erschienen in:

02.05.2023 | Sleep Breathing Physiology and Disorders • Original Article

Role of galectin-3 as a biomarker in obstructive sleep apnea: a systematic review and meta-analysis

verfasst von: Amirmohammad Khalaji, Nikan Amirkhani, Sourena Sharifkashani, Amir Hossein Behnoush

Erschienen in: Sleep and Breathing | Ausgabe 6/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Because obstructive sleep apnea (OSA) is a prevalent condition, biomarkers for OSA would be very useful. Galectin-3 has gained attention as a marker for several diseases. The aim of this study was to investigate the association between circulating galectin-3 levels and OSA.

Methods

PubMed, Scopus, Embase, and Web of Science were explored to find the studies evaluating galectin-3 in OSA and controls, within different severities of OSA, or before and after continuous positive airway pressure (CPAP) treatment in cases with OSA. We used random-effect meta-analysis to calculate standardized mean differences (SMD) along with 95% confidence intervals (CI). Newcastle–Ottawa Scale was used assessment of the risk of bias in studies.

Results

An initial search resulted in 289 results. After exclusion of duplicate studies, screening of titles/abstracts and assessments of full texts, six studies were included comprised of 987 cases with a mean age of 54.4 years. Meta-analysis showed that there were significantly higher galectin-3 circulating levels in patients with OSA than in healthy controls (SMD 0.80, 95% CI 0.30 to 1.31, p value < 0.01). Severe OSA was related to higher levels of galectin-3, in comparison to non-severe OSA (SMD 0.76, 95% CI 0.29 to 1.22, p value < 0.01). CPAP therapy also significantly reduced galectin-3 peripheral levels in patients with OSA (SMD − 3.55, 95% CI − 6.90 to − 0.20, p value = 0.04).

Conclusion

The findings suggest that Galectin-3 may have potential utility as a biomarker in patients with OSA. Further research is needed to demonstrate its role in pathophysiology, as well as its possible use in diagnosis and prognosis.

Nur mit Berechtigung zugänglich

Rundo JV (2019) Obstructive sleep apnea basics. Clevel Clin J Med 86(9 suppl 1):2–9

Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N et al (2015) Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med 3(4):310–318PubMedPubMedCentral

Senaratna CV, Perret JL, Lodge CJ, Lowe AJ, Campbell BE, Matheson MC et al (2017) Prevalence of obstructive sleep apnea in the general population: a systematic review. Sleep Med Rev 34:70–81PubMed

Young T, Evans L, Finn L, Palta M (1997) Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep 20(9):705–706PubMed

Kapur VK, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K et al (2017) Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med 13(3):479–504PubMedPubMedCentral

Gottlieb DJ, Punjabi NM (2020) Diagnosis and management of obstructive sleep apnea: a review. JAMA 323(14):1389–1400PubMed

Newlaczyl AU, Yu LG (2011) Galectin-3–a jack-of-all-trades in cancer. Cancer Lett 313(2):123–128PubMed

Saccon F, Gatto M, Ghirardello A, Iaccarino L, Punzi L, Doria A (2017) Role of galectin-3 in autoimmune and non-autoimmune nephropathies. Autoimmun Rev 16(1):34–47PubMed

Dong R, Zhang M, Hu Q, Zheng S, Soh A, Zheng Y et al (2018) Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review). Int J Mol Med 41(2):599–614PubMed

10.

Sciacchitano S, Lavra L, Morgante A, Ulivieri A, Magi F, De Francesco GP et al (2018) Galectin-3: one molecule for an alphabet of diseases, from A to Z. Int J Mol Sci 19(2):379

11.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71PubMedPubMedCentral

12.

Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M et al (2000) The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Oxford

13.

Luo D, Wan X, Liu J, Tong T (2018) Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat Methods Med Res 27(6):1785–1805PubMed

14.

Wan X, Wang W, Liu J, Tong T (2014) Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 14:135PubMedPubMedCentral

15.

Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ et al (2019) Cochrane handbook for systematic reviews of interventions. John Wiley & Sons, Hoboken

16.

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101PubMed

17.

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629–634PubMedPubMedCentral

18.

Cicco S, Castellana G, Marra L, Di Lecce V, Carratù P, Prete M et al (2021) Galectin-3 and neutrophil-to-lymphocyte ratio are indicative of heart remodelling and disease severity in patients with obstructive sleep apnoea. Sleep Med 82:117–124PubMed

19.

Kondratavičienė L, Tamulėnaitė E, Vasylė E, Januškevičius A, Ereminienė E, Malakauskas K et al (2022) Changes in left heart geometry, function, and blood serum biomarkers in patients with obstructive sleep apnea after treatment with continuous positive airway pressure. Medicina (Kaunas) 58(11):1511

20.

Pusuroglu H, Somuncu U, Bolat I, Akgul O, Ornek V, Yıldırım HA et al (2017) Galectin-3 is associated with coronary plaque burden and obstructive sleep apnoea syndrome severity. Kardiol Pol 75(4):351–359PubMed

21.

Singh M, Hanis CL, Redline S, Ballantyne CM, Hamzeh I, Aguilar D (2019) Sleep apnea and galectin-3: possible sex-specific relationship. Sleep Breath 23(4):1107–1114PubMedPubMedCentral

22.

Slouka D, Kucera R, Gal B, Betka J, Skalova A (2019) Biomarkers - a possibility for monitoring of obstructive sleep apnea syndrome. Neuro Endocrinol Lett 40(2):85–92PubMed

23.

Zong D, Liu X, Shen C, Liu T, Ouyang R (2022) Involvement of Galectin-3 in neurocognitive impairment in obstructive sleep apnea via regulating inflammation and oxidative stress through NLRP3. Sleep Med 101:1–10PubMed

24.

Rundo JV (2019) Obstructive sleep apnea basics. Cleve Clin J Med 86(9 Suppl 1):2–9PubMed

25.

Orrù G, Storari M, Scano A, Piras V, Taibi R, Viscuso D (2020) Obstructive sleep apnea, oxidative stress, inflammation and endothelial dysfunction-an overview of predictive laboratory biomarkers. Eur Rev Med Pharmacol Sci 24(12):6939–6948PubMed

26.

Bencharit S, Redenz RG, Brody ER, Chiang H (2021) Salivary biomarkers associated with obstructive sleep apnea: a systematic review. Expert Rev Mol Diagn 21(2):223–233PubMed

27.

Khalaji A, Behnoush AH, Shobeiri P, Saeedian B, Teixeira AL, Rezaei N (2022) Association between brain-derived neurotrophic factor levels and obstructive sleep apnea: a systematic review and meta-analysis. Sleep Breath

28.

Nowak N, Engler A, Thiel S, Stöberl AS, Sinues P, Zenobi R et al (2021) Validation of breath biomarkers for obstructive sleep apnea. Sleep Med 85:75–86PubMed

29.

Behnoush AH, Khalaji A, Alemohammad SY, Kalantari A, Cannavo A, Dimitroff CJ (2023) Galectins can serve as biomarkers in COVID-19: a comprehensive systematic review and meta-analysis. Front Immunol 14:1127247PubMedPubMedCentral

30.

Jiang J, Yang B, Sun Y, Jin J, Zhao Z, Chen S (2021) Diagnostic value of serum concentration of galectin-3 in patients with heart failure with preserved ejection fraction. Front Cardiovasc Med 8:829151PubMed

31.

Liu YH, D’Ambrosio M, Liao TD, Peng H, Rhaleb NE, Sharma U et al (2009) N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. Am J Physiol Heart Circ Physiol 296(2):H404–H412PubMed

32.

Filipe MD, Meijers WC, Rogier van der Velde A, de Boer RA (2015) Galectin-3 and heart failure: prognosis, prediction & clinical utility. Clin Chim Acta 443:48–56PubMed

33.

Ho JE, Yin X, Levy D, Vasan RS, Magnani JW, Ellinor PT et al (2014) Galectin 3 and incident atrial fibrillation in the community. Am Heart J 167(5):729–34.e1PubMedPubMedCentral

34.

Lin YH, Lin LY, Wu YW, Chien KL, Lee CM, Hsu RB et al (2009) The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 409(1–2):96–99PubMed

35.

Osorio RS, Martínez-García M, Rapoport DM (2022) Sleep apnoea in the elderly: a great challenge for the future. Eur Respir J 59(4):2101649

36.

Vanek J, Prasko J, Genzor S, Ociskova M, Kantor K, Holubova M et al (2020) Obstructive sleep apnea, depression and cognitive impairment. Sleep Med 72:50–58PubMed

37.

Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Milovanovic MZ, Nikolic IG et al (2013) Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes 62(6):1932–1944PubMedPubMedCentral

38.

Siew JJ, Chen H-M, Chen H-Y, Chen H-L, Chen C-M, Soong B-W et al (2019) Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease. Nat Commun 10(1):3473PubMedPubMedCentral

39.

Liu X, Ma Y, Ouyang R, Zeng Z, Zhan Z, Lu H et al (2020) The relationship between inflammation and neurocognitive dysfunction in obstructive sleep apnea syndrome. J Neuroinflammation 17(1):229PubMedPubMedCentral

40.

Zhou L, Chen P, Peng Y, Ouyang R (2016) Role of oxidative stress in the neurocognitive dysfunction of obstructive sleep apnea syndrome. Oxid Med Cell Longev 2016:9626831PubMedPubMedCentral

41.

Menini S, Iacobini C, BlasettiFantauzzi C, Pesce CM, Pugliese G (2016) Role of galectin-3 in obesity and impaired glucose homeostasis. Oxid Med Cell Longev 2016:9618092PubMed

42.

Pugliese G, Iacobini C, Ricci C, BlasettiFantauzzi C, Menini S (2014) Galectin-3 in diabetic patients. Clin Chem Lab Med 52(10):1413–1423PubMed

43.

Pugliese G, Iacobini C, Pesce CM, Menini S (2015) Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology 25(2):136–150PubMed

44.

Weigert J, Neumeier M, Wanninger J, Bauer S, Farkas S, Scherer MN et al (2010) Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes. J Clin Endocrinol Metab 95(3):1404–1411PubMed

45.

Fryk E, Silva VRR, Jansson PA (2022) Galectin-1 in obesity and type 2 diabetes. Metabolites 12(10):930

46.

Pang J, Rhodes DH, Pini M, Akasheh RT, Castellanos KJ, Cabay RJ et al (2013) Increased adiposity, dysregulated glucose metabolism and systemic inflammation in Galectin-3 KO mice. PLoS ONE 8(2):e57915PubMedPubMedCentral

47.

Martínez-Martínez E, Calvier L, Rossignol P, Rousseau E, Fernández-Celis A, Jurado-López R et al (2016) Galectin-3 inhibition prevents adipose tissue remodelling in obesity. Int J Obes (Lond) 40(6):1034–1038PubMed

48.

Marín-Royo G, Gallardo I, Martínez-Martínez E, Gutiérrez B, Jurado-López R, López-Andrés N et al (2018) Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity. Dis Model Mech 11(2):dmm032086

49.

Chen B, Drager LF, Peker Y, Vgontzas AN, Phillips CL, Hoyos CM et al (2021) Effect of continuous positive airway pressure on weight and local adiposity in adults with obstructive sleep apnea: a meta-analysis. Ann Am Thorac Soc 18(10):1717–1727PubMed

50.

ZeytinliAksit M, DemetArslan F, Karakoyun I, Aydin C, Turgut E, Parildar H et al (2022) Galectin-3 levels and inflammatory response in patients undergoing bariatric surgery. Cytokine 151:155793

51.

Gelardi M, Carbonara G, Maffezzoni E, Marvisi M, Quaranta N, Ferri R (2012) Regular CPAP utilization reduces nasal inflammation assessed by nasal cytology in obstructive sleep apnea syndrome. Sleep Med 13(7):859–863PubMed

52.

Karamanlı H, Özol D, Ugur KS, Yıldırım Z, Armutçu F, Bozkurt B et al (2014) Influence of CPAP treatment on airway and systemic inflammation in OSAS patients. Sleep Breath 18(2):251–256PubMed

53.

Lacedonia D, Salerno FG, Carpagnano GE, Sabato R, Depalo A, Foschino-Barbaro MP (2011) Effect of CPAP-therapy on bronchial and nasal inflammation in patients affected by obstructive sleep apnea syndrome. Rhinology 49(2):232–237PubMed

54.

Zuberi RI, Hsu DK, Kalayci O, Chen HY, Sheldon HK, Yu L et al (2004) Critical role for galectin-3 in airway inflammation and bronchial hyperresponsiveness in a murine model of asthma. Am J Pathol 165(6):2045–2053PubMedPubMedCentral

Titel: Role of galectin-3 as a biomarker in obstructive sleep apnea: a systematic review and meta-analysis
verfasst von: Amirmohammad Khalaji
Nikan Amirkhani
Sourena Sharifkashani
Amir Hossein Behnoush
Publikationsdatum: 02.05.2023
Verlag: Springer International Publishing
Erschienen in: Sleep and Breathing / Ausgabe 6/2023
Print ISSN: 1520-9512
Elektronische ISSN: 1522-1709
DOI: https://doi.org/10.1007/s11325-023-02842-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Role of galectin-3 as a biomarker in obstructive sleep apnea: a systematic review and meta-analysis